Historical Valuation
MacroGenics Inc (MGNX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.83 is considered Fairly compared with the five-year average of -3.36. The fair price of MacroGenics Inc (MGNX) is between 0.92 to 7.50 according to relative valuation methord.
Relative Value
Fair Zone
0.92-7.50
Current Price：1.79
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
MacroGenics Inc (MGNX) has a current Price-to-Book (P/B) ratio of 1.52. Compared to its 3-year average P/B ratio of 2.90 , the current P/B ratio is approximately -47.59% higher. Relative to its 5-year average P/B ratio of 3.10, the current P/B ratio is about -50.92% higher. MacroGenics Inc (MGNX) has a Forward Free Cash Flow (FCF) yield of approximately -161.77%. Compared to its 3-year average FCF yield of -45.88%, the current FCF yield is approximately 252.60% lower. Relative to its 5-year average FCF yield of -40.38% , the current FCF yield is about 300.65% lower.
P/B
Median3y
2.90
Median5y
3.10
FCF Yield
Median3y
-45.88
Median5y
-40.38
Competitors Valuation Multiple
AI Analysis for MGNX
The average P/S ratio for MGNX competitors is 1.76, providing a benchmark for relative valuation. MacroGenics Inc Corp (MGNX.O) exhibits a P/S ratio of 1.83, which is 3.84% above the industry average. Given its robust revenue growth of -34.21%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MGNX
1Y
3Y
5Y
Market capitalization of MGNX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MGNX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MGNX currently overvalued or undervalued?
MacroGenics Inc (MGNX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.83 is considered Fairly compared with the five-year average of -3.36. The fair price of MacroGenics Inc (MGNX) is between 0.92 to 7.50 according to relative valuation methord.
What is MacroGenics Inc (MGNX) fair value?
MGNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MacroGenics Inc (MGNX) is between 0.92 to 7.50 according to relative valuation methord.
How does MGNX's valuation metrics compare to the industry average?
The average P/S ratio for MGNX's competitors is 1.76, providing a benchmark for relative valuation. MacroGenics Inc Corp (MGNX) exhibits a P/S ratio of 1.83, which is 3.84% above the industry average. Given its robust revenue growth of -34.21%, this premium appears unsustainable.
What is the current P/B ratio for MacroGenics Inc (MGNX) as of Jan 09 2026?
As of Jan 09 2026, MacroGenics Inc (MGNX) has a P/B ratio of 1.52. This indicates that the market values MGNX at 1.52 times its book value.
What is the current FCF Yield for MacroGenics Inc (MGNX) as of Jan 09 2026?
As of Jan 09 2026, MacroGenics Inc (MGNX) has a FCF Yield of -161.77%. This means that for every dollar of MacroGenics Inc’s market capitalization, the company generates -161.77 cents in free cash flow.
What is the current Forward P/E ratio for MacroGenics Inc (MGNX) as of Jan 09 2026?
As of Jan 09 2026, MacroGenics Inc (MGNX) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of MacroGenics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for MacroGenics Inc (MGNX) as of Jan 09 2026?
As of Jan 09 2026, MacroGenics Inc (MGNX) has a Forward P/S ratio of 1.83. This means the market is valuing MGNX at $1.83 for every dollar of expected revenue over the next 12 months.